- Home
- IMAB vs ANIX Comparison
IMAB vs ANIX Comparison
Compare IMAB & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ANIX
- Stock Information
- Founded
- IMAB 2014
- ANIX 1982
- Country
- IMAB United States
- ANIX United States
- Employees
- IMAB N/A
- ANIX N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- ANIX Health Care
- Exchange
- IMAB Nasdaq
- ANIX Nasdaq
- Market Cap
- IMAB 79.9M
- ANIX 84.7M
- IPO Year
- IMAB 2020
- ANIX 1987
- Fundamental
- Price
- IMAB $0.80
- ANIX $2.66
- Analyst Decision
- IMAB Strong Buy
- ANIX Strong Buy
- Analyst Count
- IMAB 3
- ANIX 2
- Target Price
- IMAB $8.00
- ANIX $8.50
- AVG Volume (30 Days)
- IMAB 234.1K
- ANIX 99.0K
- Earning Date
- IMAB 03-21-2025
- ANIX 03-18-2025
- Dividend Yield
- IMAB N/A
- ANIX N/A
- EPS Growth
- IMAB N/A
- ANIX N/A
- EPS
- IMAB N/A
- ANIX N/A
- Revenue
- IMAB $569,464.00
- ANIX N/A
- Revenue This Year
- IMAB N/A
- ANIX N/A
- Revenue Next Year
- IMAB N/A
- ANIX N/A
- P/E Ratio
- IMAB N/A
- ANIX N/A
- Revenue Growth
- IMAB N/A
- ANIX N/A
- 52 Week Low
- IMAB $0.76
- ANIX $2.07
- 52 Week High
- IMAB $2.00
- ANIX $4.20
- Technical
- Relative Strength Index (RSI)
- IMAB 31.17
- ANIX 40.85
- Support Level
- IMAB $0.76
- ANIX $2.80
- Resistance Level
- IMAB $0.93
- ANIX $3.30
- Average True Range (ATR)
- IMAB 0.07
- ANIX 0.22
- MACD
- IMAB -0.01
- ANIX -0.05
- Stochastic Oscillator
- IMAB 18.03
- ANIX 11.11
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.